ArticleiScience2026
Integrative multiomics analysis identifies RARRES2 as a regulator of keloid pathogenesis through STAT3/HSPG2 signaling axis.
Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The molecular regulators behind the pathogenesis of keloid have not been fully determined. Through Mendelian randomization and multiomics analyses, we identified retinoic acid receptor responder 2 (RARRES2) as a causal risk factor for keloid. We further found that RARRES2 is mainly enriched in fibroblasts in various human tissues. RARRES2 is highly expressed in keloid tissue and mainly enriched in fibroblasts of keloid. Heparan sulfate proteoglycan 2 (HSPG2) was identified as a potential downstream effector molecule of RARRES2, and p-STAT3 was proven to bind to the promoter region of HSPG2. We demonstrated that RARRES2 promotes the expression of HSPG2 by phosphorylating STAT3. Moreover, we confirmed that RARRES2 exerts the pro-scarring effect through the STAT3/HSPG2 pathway in primary fibroblasts and animal models. Overall, our results demonstrate that RARRES2 is a key regulator of keloid pathogenesis through STAT3-mediated HSPG2 activation, and RARRES2 can serve as a specific molecular target in patients with keloid.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.